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Abstract
Diseases involve complex modifications to the cellular machinery. The gene expression profile of the affected
cells contains characteristic patterns linked to a disease. Hence, new biological knowledge about a disease can be
extracted from these profiles, improving our ability to diagnose and assess disease risks. This knowledge can be
used for drug re-purposing, or by physicians to evaluate a patient’s condition and co-morbidity risk.
Here, we consider differential gene expressions obtained by microarray technology for patients diagnosed with
various diseases. Based on these data and cellular multi-scale organization, we aim at uncovering disease–disease
links, disease–gene and disease–pathways associations. We propose neural networks with structures based on the
multi-scale organization of proteins in a cell into protein complexes and pathways. We show that these models
are able to correctly predict the diagnosis for the majority of patients. Through the analysis of the trained
models, we predict disease–disease, disease–pathway, and disease–gene associations and validate the predictions
by comparisons to known interactions and literature search, proposing putative explanations for the predictions.
Introduction
A disease is often described by symptoms and affected tissues. However, to give a definite diagnosis, physicians often
need to analyse patient samples (e.g., blood samples, or biopsies) for characteristic disease indicators, commonly
referred to as disease biomarkers. These may include dis-regulated genes, or pathways [1, 2]. Taking into consideration
the history of a patient’s past and present conditions identifying genetic predispositions, as well as considering
associations between diseases, aid in achieving as accurate diagnostics and treatments [3]. By also taking advantage
of the increasing availability of large scale molecular data, precision medicine aims at improving the understanding
of the molecular base of diseases on individual basis, as well as the relationships between different conditions [4, 5].
The benefits from such work are multiple and include drug re-purposing and identification of new disease biomarkers
to improve treatments and diagnoses.
Many studies have investigated disease–gene and disease–pathway associations with the objective of improving
diagnoses [6, 7, 8, 9]. For instance, Zhao et al. [8] propose a ranking of disease genes based on gene expression
and protein interactions using Katz-centrality. Hong et al. [9] design a tool that identifies significantly disrupted
pathways by comparing patient gene expression against controls collected from other experiments. Cogswell et al.
[10] identify putative gene and pathway biomarkers through change in miRNA in Alzheimer’s disease. In specific
cancers, Abeel et al. [6] use support vector machines and ensemble feature selection methods to select putative gene
biomarkers.
A key issue is that most of these studies consider diseases in isolation, i.e. comparing patients having a disease
of interest to healthy individuals while the predicted biomarkers could be shared between various diseases. This
limits the discriminative potential of such studies for accurate diagnoses. Indeed, network medicine has shown that
diseases can share significant molecular background, as evidenced by numerous studies based on patient historical
records [11, 3, 12], biological knowledge of the diseases [4, 5, 13], or patient gene expression profiles [14]. For instance,
Goh et al. [4] build a disease network, which connects diseases that share at least one gene which when mutated
is linked to both conditions. Lee et al. [5] construct a disease network of metabolic diseases, connecting pairs of
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diseases for which associated mutated enzymes catalyze adjacent metabolic reactions. Hidalgo et al. [11] take a
different approach by building a disease network based on disease co-morbidities, i.e. two diseases are connected if
they tend to co-occur significantly in the patient populations. They used Medicare records of elderly patients to build
the network. He et al. [13] propose PCID (Predicting Comorbidity by Integrating Data), an approach to predict
disease co-morbidities by aggregating disease similarity scores derived from different data including protein–protein
interactions (PPIs), pathways, and functional annotations.
Sa´nchez-Valle et al. [14] define a disease network, named the Disease Molecular Similarity Network (DMSN)
based on patient genes expression profiles. In their study, the DMSN is generated using positive (negative) relative
risk (RR) as a measure of disease similarity (dissimilarity, resp.) that is then interpreted as an estimate of risk. First,
the patients associated with a given disease are clustered into subgroups to account for disease heterogeneity. Then,
a similarity of the gene expression of patients is computed between patients having different diseases generating a
patient–patient network. Next, using the RR score, diseases are related to each other. The resulting network is
directed and each edge is associated to a positive or negative label indicating either an increased or decreased risk of
developing the target disease if the patient has the source disease. The underlying assumption is that having a given
disease can increase the risk of developing a disease characterized by a similar gene expression profile.
In these various approaches, a key issue is that either a single data source is used, such as disease–gene mutational
data [4], or no new biological knowledge about a specific disease could be derived from the results (e.g., PCID [13]).
In this work, we propose an integrative framework based on artificial neural networks (NN) to predict disease–
disease links, as well as disease–pathway and disease–gene associations. We test three neural networks trained to
predict patients’ diagnoses based on differential gene expression. The NNs’ structures are designed to mimic the
cellular multi-scale organization by integrating gene–pathway, gene–protein complex and protein complex–pathway
annotations. This approach follows on from a body of work aiming to build neural networks based on prior information
defining the structure of the network [15]. For instance, Ma et al. [16] build a neural network using the Gene Ontology
[17] directed acyclic graph as a template for the connections. The neural network, named DCell, is then trained to
predict phenotype related to cellular fitness from genotype data. The trained DCell predicts cellular growth almost
as accurately as laboratory observations.
We show that our framework achieves good accuracy scores on our dataset. We hypothesize that for each patient,
the output vector from each NN gives a personalized disease risk vector between the patient and each of the possible
diseases. From those personalized disease risk representations, we derive a directed disease–disease network capturing
positive risk associations between diseases. We show that the links are biologically relevant and can be corroborated
by existing disease co-morbidities, or by molecular evidence. We manually search the literature to validate our top
disease–disease predictions. We show that by analysing the trained NNs, i.e. the underlying matrices, we can extract
biological knowledge relevant for each disease. Specifically, we use the trained NN to predict novel disease–pathway
and disease–gene links. We show that our predictions are biologically relevant and we verify the top predictions
through manual literature curation ensuring that the sources do not use the same data, to mitigate the risk of
argument circularity.
1 Material & Methods
1.1 Datasets
We use the original dataset described by Sa´nchez-Valle et al. [14]. Briefly, the data consists of multiple datasets
of gene expression captured with micro-array technology [18]. The datasets are downloaded from Gene Expression
Omnibus (GEO, [19]) and ArrayExpress [20] databases. Each dataset contains measurements from healthy (controls)
and affected (patients) subjects. For a given dataset, the measurements originate from bulk samples extracted from
the same tissue in each subject. Not all datasets use the same tissue for measurements, as diseases do not necessarily
affect the same tissue. Each patient is diagnosed with a single disease. For comparisons, the data is normalized
by using the frozen robust multiarray procedure [21] to remove experimental bias. Furthermore, to remove tissue
effects, each patient sample is normalised against all the control samples of its original dataset using the Limma
method [22]. Up to this point, the data is identical to those used to derive the DMSN network [14]. Then we use the
corrected p-values output by Limma to define for each patient a vector of size corresponding to the number of genes
and in which the ith entry is equal to 1, −1, or 0 depending on whether the ith gene is significantly (with 5% cutoff)
over-, under-, or normally expressed, respectively, for that patient. Additionally, we exclude patients that have no
significantly deregulated genes, as we cannot learn anything from them.
The set of diseases is curated by hand for associations with Disease Ontology codes [23], standard ICD9 and
ICD10 codes, MeSH terms and OMIM codes [24]. Some of the datasets come from studies investigating subtypes
of diseases that are studied by projects linked to other datasets. Based on the number of patients in each study,
2
those datasets were either merged with the more global disease, or the patients associated with the more global
disease were dropped from the study. Specifically, we drop the global disease if the subtype has many more patients
associated with it and merge otherwise. Finally, we exclude diseases that have less than 10 associated patients to
capture disease heterogeneity in the final dataset and to have sufficient data for each disease to split in a training
and testing set.
We also collect pathway and protein complex annotations from Reactome database [25] (accessed December
2018). We restrict our study to the lowest pathways in the hierarchy to avoid dealing with pathway interactions (i.e.
pathways containing other pathways). We further restrict our set of pathways to the ones that have a Traceable
Author Statement (TAS). We apply the same selection process to protein complexes, which are also annotated with
pathway data in Reactome.
The final dataset contains 4, 788 samples (patients) from 43 tissues and a total of 83 diseases. In total, 20, 525
genes have their expressions measured, but only a subset is used as input to our method described in the following
section, as we restrict ourselves to genes associated to at least one pathway, which leaves 9, 247 genes.
1.2 Neural network based data–integration framework
We propose three neural networks (NN) predicting a patient diagnosis based on differential gene expression. The
structures of two of the neural networks are based on molecular organization, i.e. by gene–complex and gene–pathway
annotations downloaded from Reactome (see Figure 1). We integrate molecular organization data into our model to
reflect the idea that complex diseases, such as cancer, can be the results of the perturbations of groups of genes, as
opposed to a single gene. Using Reactome data allows us to incorporate prior knowledge into our model in the form
of biologically meaningful groupings of genes.
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Figure 1: Example of neural network architecture. For the first two layers, the connections are defined by biological
information, e.g. a unit representing a gene is connected to all the protein complexes that the gene is involved in.
We do not add any prior knowledge on the last layer, thus it is fully connected.
In our case, the objective of a NN is to predict a patient’s diagnosis from the corresponding differential gene expres-
sion profile. A neural network can be expressed as a series of matrix multiplications interleaved with non-linear func-
tions, i.e. the outputY of a neural network with n−1 hidden layers can be written asY = fn (Wnfn−1 (. . . f1((W1X)))
where X represents the input data, Wi the weights of layer i, and fi(·) the non-linear function applied to the output
of the ith layer. The optimization problem can be written as the minimization of the loss function L = g
(
Yˆ,Y
)
,
where Yˆ is the objective, or ground truth, and g(·) is a predefined function. We design three NN architectures as
follows
Y1 = s
(
W1X
)
(1)
Y2 = s
(
W2
2
f
(
W2
1
X
))
(2)
Y3 = s
(
W3
3
f
(
W3
2
f
(
W3
1
X
)))
(3)
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where s is the softmax function [26], typically used for multiclass classification problems, and f is the hyperbolic
tangent, which is chosen to allow a hidden unit to have either positive or negative value (i.e. up- or down-regulation
for protein complexes or pathways). The first setting corresponds to a multiclass logistic regression (no hidden layer)
that is used as a reference model, the second setting corresponds to a neural network with only one hidden layer
capturing gene–pathway links, and the last setting corresponds to a neural network with two hidden layers, capturing
gene–complex and complex–pathway links, respectively. We use the classical cross-entropy function to define our
loss function L. Hereafter, we refer to these models as NN1, NN2, and NN3, respectively.
Matrices X and Yˆ represent our data. Each column of X corresponds to the differential gene expression of a
patient, and each column of Yˆ corresponds to a patient’s diagnosis (the prediction of which is the objective of the
framework). W1 ∈ Rnd×ng , W2
2
∈ Rnd×np , and W3
3
∈ Rnd×np correspond to fully-connected layers. The layer
corresponding to W3
1
∈ Rnc×ng represents protein complex membership of the genes, i.e. the trainable weights of
the matrix correspond only to entries (i, j) where gene j is part of the ith protein complex. Similarly, matrices
W2
1
∈ Rnp×ng and W3
2
∈ Rnp×nc represent pathway memberships of genes and protein complexes, respectively. Note
that in the last setting, if a gene is involved in a pathway independently of a protein complex, we add skip connections
from the input (gene layer) to the pathways layer. Each formulation has a different number of parameters (or free
weights): (573, 314), (137, 838), and (150, 341), respectively. Note that, due to this imbalance, we do not expect NN2
and NN3 to outperform NN1 in the diagnosis prediction task.
The neural networks are implemented with Tensorflow [27].
1.3 Predicting disease–disease, disease–pathway, and disease–gene relationships
Once a neural network is trained, for each patient we interpret the vector of logits, which corresponds to the output
of a NN without the softmax transformation (applied only for the learning phase), as a personalized disease risk
vector for the patient, giving a score for each disease in our dataset. We chose to consider the logits as they give a
richer representation, with positive and negative scores, and avoid the patient-specific normalization implied by the
softmax operation. We make the assumption that for a patient with a given diagnosis, alternative diseases having a
positive score in a NN output are related to the patient diagnosis. By taking averages across all patients having a
given disease, we derive directed disease–disease relationships. Formally, the score sij from a disease i to a disease j
is given by
sij =
1
|Pi|
∑
p∈Pi
logitspj ,
where, for simplicity, we amalgamate a disease (or a patient) with its index in the data, Pi corresponds to the set of
patients having disease i, and logitspj gives the logit of disease j for patient p. We postulate that diseases connected
positively are linked and that the link implies a direction from the first disease to the second, i.e. that having the
first disease puts one at a higher risk of developing the second. Existing directed disease–disease networks are not
suitable to test our approach as either they are not available for confidentiality reasons [12], or they have a too small
overlap with our disease set [3]. Thus, this hypothesis will be validated through literature curation.
To identify associations between diseases and genes or pathways, we analyze the variations of each disease output
score in response to a change in value of a given unit (representing a pathway, or a gene). This approach is often
referred to as sensitivity analysis [28]. Formally, the local variations δf of a single-argument function f due to a
change δx = x− x0 in input can be approximated with the first order Taylor expansion as
δf(x) =
df
dx
(x0)δx +O(x
2).
Thus, the magnitude of the local variations of f with respect to perturbation δx from x0 is given by |
df
dx
(x0)|. Based
on this approximation, we extract from each neural network a score between an entity represented by a unit of
the neural network (e.g, a pathway, or a gene) and each disease (output unit). Specifically, for a neural network
NN, we denote nni : [0, 1]
ni 7→ Rno the function corresponding to the operation of a neural network NN from the
ni outputs of layer i to the final no logits of the neural network. E.g., for NN3 described in Section 1.2, we have
nn1
3
(x) = W3
3
f
(
W3
2
x
)
. Then, the association score si,j,k between the j
th output unit of layer i, uij , of neural network
NN, and disease k is given by
si,j,k =
∣∣∣∣∣
[
∂nni
∂uij
(x0)
]
k
∣∣∣∣∣ ,
where the reference point is chosen as the null vector, x0 = 0, which corresponds implicitly to a healthy state in our
formulation.
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We test this scoring approach for the prediction of disease–gene and disease–pathway associations.
2 Results & Discussion
2.1 Classification performances
For each network, we perform a 10-fold cross-validation to fix the number of training epochs. Specifically, we compute
the average number of epochs at which the test loss is the smallest across the runs. As the dataset is imbalanced, we
use stratification to split the data, ensuring that at least one patient per disease is in the test set. Using this number
of epochs, we perform another 10-fold cross-validation to evaluate the performance of our models. The networks are
trained using an Adam optimizer [29] with learning rate 0.01.
We compare the performances of our models against Random Forest (RF), Bernoulli Naive Bayes (nB), and
Support Vector Machine (SVM) algorithms (we use the implementation available through the scikit-learning python
package [30]). We perform 10-fold cross-validation for the algorithms to fix the hyperparameters (numbers of trees,
smoothing parameter and regularisation coefficient, respectively) and retain the best performing models in terms of
cross-entropy loss (the objective function of the neural networks).
We evaluate performances by computing 3 different scores: cross-entropy loss (CEL), micro- and macro-average
accuracies (Accµ and AccM ). Accµ give a measure of the overall accuracy of each classifier, while AccM gives an
average of the accuracy across the different classes (diseases). The CEL gives a more nuanced score that relates to
the confidence of the classifier. A relatively small CEL means that the output probability distribution of a classifier
is closer to the deterministic one-hot encoding of the true labeling, i.e. the classifier gives a higher probability to the
true class and a very small probability to the other classes.
Algorithm CEL Accµ AccM
NN1 1.01± 0.07 0.84± 0.01 0.76± 0.01
NN2 1.09± 0.06 0.80± 0.01 0.71± 0.02
NN3 1.14± 0.11 0.81± 0.01 0.72± 0.03
RF 1.56± 0.24 0.80± 0.01 0.70± 0.03
nB 10.63± 0.55 0.66± 0.01 0.60± 0.02
SVM 1.42± 0.04 0.72± 0.02 0.59± 0.02
Table 1: Performances of different classifiers in terms of cross-entropy loss (CEL), micro- and macro-average accura-
cies (Accµ and AccM , respectively). Each score is computed across the 10-fold cross-validation and we provide the
standard deviation. Bold scores highlight the best scores for each metric.
We observe that the neural networks give overall better performances than the RF, nB, and SVM classifiers as
measured by our three metrics (see 1). The best model appears to be the multiclass-logistic regression (i.e., the
first neural network, NN1), which corresponds to the most complex neural network model in terms of the number of
parameters, since NN1 has ∼ 4 times more parameters than NN2 and NN3.
To complete the picture, we test at which rank the correct prediction is in the output of each classifier and
compute the area under the resulting cumulative plot (see 2). We observe that, in terms of area under the curve,
the RF classifier slightly outperform NN1. This suggests that the correct diagnosis is generally assigned a higher
probability, on average, by the RF classifier when compared to the other methods.
NN2 and NN3 demonstrate better, or at least on-par, performances when compared to other classifiers. This
observation justifies the relevance of our models. Moreover, we show, in the following Sections, that the trained
NN2 and NN3 models can be more successfully exploited than NN1 to extract biological information. However, this
analysis shows that using biological knowledge to guide the structure of neural networks, in the limit of the models
proposed, does not improve classification performance compared to the multiclass logistic regression (NN1) and only
offers slight improvement when compared to a RF classifier (see 1).
2.2 Our NN-framework predicts disease–disease relationships
Hereafter, we consider for each model (NN1, NN2, and NN3) the trained NN that gave the lowest cross-entropy
loss during the 10-fold cross validation, as well as the entire data. We investigate the disease–disease associations
obtained for each setting of the NN to understand and validate the positive associations that we predict (see details
in Methods). We test our set of associations against four undirected “ground-truth” networks consisting of pairs of
diseases that are connected because of 1) the two diseases are mentioned together in an abstract, 2) the two diseases
5
0 20 40 60 80
Rank
0.0
0.2
0.4
0.6
0.8
1.0
Cu
m
ul
at
iv
e 
pe
rc
en
ta
ge
NN1 - auc=  80.3
NN2 - auc=  79.2
NN3 - auc=  79.0
RF - auc=  80.5
nB - auc=  74.9
SVM - auc=  79.9
Random
Figure 2: Cumulative plot giving the percentage of patients for which the correct diagnosis is at or below a given
rank in the output of each algorithm. Standard deviations are represented with the thickness of the lines.
are co-morbid as reported by Hidalgo et al. [11], or the two diseases affect at least 3) a gene, or 4) a pathway in
common. All ground-truths are restricted to our set of diseases. We compare the performance of our models against
the DMSN network [14], restricted to our set of diseases, which is generated from the same original data. We only
use the DMSN as other directed disease networks are either too small for comparisons [3, 31] or the network is not
available due to privacy [12]. For all tested models, we compute precision and recall scores, i.e. we compute the
percentage of predicted pairs that are also in the ground-truth (precision) and the percentage of associations in the
ground-truth that are in our predicted set (recall). We present the results using the harmonic mean, f1 score, of the
precision and recall (see Table 2).
Model Literature Co-morbidity Common Genes Common Pathways Global
DMSN 0.46 (67%) 0.42 (51%) 0.35 (41%) 0.31 (37%) 89%
NN 1 0.22 (68%) 0.23 (53%) 0.22 (50%) 0.14 (35%) 91%
NN 2 0.45 (65%) 0.43 (50%) 0.41 (47%) 0.35 (41%) 90%
NN 3 0.46 (64%) 0.45 (52%) 0.41 (47%) 0.34 (40%) 90%
Table 2: F1 scores of the set of predictions of disease–disease relationships from different NN models, as well as
DMSN, against the four ground-truths. The scores in parenthesis correspond to the precision. The last column
gives the percentage of predicted associations that are at least present in one of the ground-truth sets. Bold scores
indicates the maximum score for each column.
Abstract mining: associated diseases tend to be mentioned together in the literature
We extract from our set of diseases the pairs that are mentioned together in at least one abstract (from NCBI’s
PubMed database, collected the 13th of December, 2018). The queries are done through the PubMed API [32]. The
obtained network is then used as ground-truth for testing our prediction accuracy.
We observe that connected diseases in our generated networks often tend to be co-mentioned in a PubMed
abstract (see Table 2) with between 64% and 68% of predicted pairs being mentioned together. The precision scores
are significant according to a hypergeometric test for all methods, NNs and DMSN, but we observe that NN1 has the
lowest f1 score due to a very low recall. This highlights that adding biological knowledge, beside gene expression, is
beneficial to the model performance. This observation holds regardless of the ground-truth considered (see Table 2).
6
Disease 1 Disease 2 Literature support
Job’s syndrome Chronic obstructive pulmonary disease
Job’s syndrome Myocardial infarction PMID:18424333
Job’s syndrome Sepsis PMID:18424333
Job’s syndrome Schizophrenia
Dengue disease Sepsis PMID:28437459
Rosacea Psoriasis PMID:28405739
Myelofibrosis Polycythemia vera
Oligodendroglioma Alzheimer’s disease
Pilocytic astrocytoma Alzheimer’s disease
Essential thrombocythemia Polycythemia vera
Table 3: Top 10 disease–disease links predicted using NN3. If found, we give the PMID of a journal article that
supports the predicted directed link between the two diseases.
To elucidate the nature of the links between the diseases, a review of the literature is required. We do so for the
disease network obtained from NN3, as it has the highest f1 score. We look at the top 10 links (presented in Table
3) and report the literature that support, or indicate the possibility of a link between two diseases.
We observe that 4 disease–disease associations out of the 10 predicted have support in the literature. We inves-
tigate the remaining disease–disease associations and look for validation.
The link between Job’s syndrome and chronic obstructive pulmonary disease is not established, however gene
STAT3 is involved in both those conditions [33, 34] and is a potential lead to connect those diseases. Furthermore,
STAT3 interacts closely with IL-10 which has been shown to be affected in both Job’s syndrome [35] and Schizophrenia
[36] suggesting a common molecular basis to those two conditions as well. Oligodendroglioma, as well as Pilocytic
astrocytoma, have not been observed to increase the risk of developping Alzheimer’s disease. However, brain tumours
and Alzheimer’s disease have both been connected to tau immunoreactivity [37], suggesting that the two diseases
share a molecular basis. Furthermore, the reciprocal associations, i.e. a direct co-morbidity between Alzheimer’s
disease and certain brain tumours, have previously been observed, such as with glioblastoma [38]. It is rarely observed
that brain tumours lead to the development of Alzheimer’s disease, possibly due to the poor prognosis associated
with most brain tumours. Myelofibrosis, polycythemia vera, and essential thrombocythemia are all part of the same
class of disease, the myeloproliferative neoplasms (MPNs), among which co-occurences have been observed [39].
This investigation demonstrates that our predicted disease–disease relationships have support in the literature.
Disease links as co-morbidities
We use the co-morbidity network constructed by Hidalgo et al. [11], restricted to our set of diseases, as a ground-
truth. The network was constructed from patients records in the USA spanning many years. In this network, nodes
correspond to three digit ICD9 codes describing the principal diagnosis at the time of a visit.
We observe that, in our models, above 50% of our predictions correspond to the existing co-morbidities (see Table
2). These are significant for three out of the four networks considered, according to the hypergeometric test, NN2
being just below the significance cut–off. We observe that NN3 gives the highest f1 score, confirming the interest
of incorporating additional biological information into the model. The f1 scores and the underlying recall scores
seem to be somewhat lower than expected. This could be due to the ground-truth network being built with elderly
patient data. With age, diseases tend to co-occur more frequently, without necessarily being related. Overall, our
predictions significantly capture the existing co-morbidities, thus validating our methodology.
Molecular evidence
As exemplified through literature curation presented above, associated diseases can involve the same genes and
pathways in the cell. We investigate if this holds for our predicted disease associations. We download curated
disease–gene associations from the DisGeNET database [40] and extract, from our set of diseases, pairs that have at
least one common gene. Similarly, we download disease–pathway associations from the Comparative Toxicogenomics
Database (CTD; [41]), and extract disease pairs that share pathways.
We observe that around 47% of our predicted links from NN2 and NN3 significantly (according to the hyperge-
ometric test) correspond to pairs of disease that share associated genes (see Table 2). Note that the ground-truth
does not consider how the genes are altered in the disease (e.g., over- or under-expressed). Our f1 scores are 17%
higher than the score of DMSN. This shows that predicted associations capture more disease links with overlap in
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genes than DMSN. The three neural networks give significant precision scores as opposed to the scores of DMSN,
which are not significant.
We obtain lower precision scores when we use the pathway based ground-truth with around 40% of links being
corroborated (see Table 2). It is worth mentioning that only about two thirds of the considered diseases are associated
to pathways in CTD database, thus precision scores should be taken with a grain of salt. We observe that our NN
models outperform DMSN here as well, with at least a 10% increase in f1 score over DMSN. The lowest scoring model
corresponds to the first setting of the NNs. This further shows that integrating biological knowledge in a neural
network improves the quality of the disease–disease predictions. However, none of the precision scores with respect to
the pathway based ground-truth are significant according to the hypergeometric test. Yet, among all diseases having
at least one pathway annotation, the number of pairs of diseases sharing at least one pathway is very high (89% of
the total number of possible pairs). It is unlikely that all of those diseases are related. We hypothesize that the larger
the number of pathways shared between diseases, the more likely it is that the two diseases are related. We test this
hypothesis using Mann-Whitney U statistical test and we observe that for all investigated models, apart from the
NN1 model, diseases that have an overlap in the associated pathways tend to share significantly more pathways than
expected by chance. The relatively low recall scores in both tests above could be explained by the fact that diseases
can affect the same pathways or genes without necessarily being co-morbid.
The above analysis shows that our predictions relate to biologically relevant information and can, to some extent,
be related to diseases sharing genes or pathways. Overall, 90% of the predicted associations can be validated as being
co-mentioned in the literature, being co-morbid diseases, sharing at least a common gene, or sharing an above average
number of pathways. These results validate our approach for the elucidation of disease-disease associations. Also, our
framework proposes new disease–pathway associations and disease–gene associations (described in Methods, Section
1.3), discussed below.
2.3 Our NN-framework uncovers molecular mechanisms of diseases
To uncover molecular mechanisms of disease, i.e., genes and pathways that are associated to specific diseases, we
extract predictions from each NN model using the approach described in Methods. We test the performance of
our predictions by using the established databases and investigate the top predictions through manual search of the
literature for the best performing model for predicting disease–pathway and disease–gene associations.
Predicting disease–pathway associations
For each model, we compute disease–pathway association scores as described in Methods and we test the validity of
our predictions by comparison with CTD database [41].
We use precision–recall and ROC curves (see Figure 3) to evaluate the performance of our approach. We observe
that both NN2 and NN3 give a marginal improvement over random and that NN2 gives better predictions. Overall
the performance of our approaches for disease–pathway association prediction appear limited. The relatively poor
performances can partially be attributed to the incompleteness of CTD database. As a complementary analysis,
we search the literature for support for the top 10 disease–pathway associations predicted with the best performing
model, NN2 (see Table 4). Note that none of these associations are reported in CTD database.
Disease Pathway Literature support
Autistic disorder R-HSA-5653890
Irritable bowel syndrome R-HSA-532668 PMID:20338921
Irritable bowel syndrome R-HSA-391906 PMID:16835707
Type 2 diabetes mellitus R-HSA-499943 doi:10.2337/diabe-tes.51.2007.S363
Asthma R-HSA-391906 PMID:8603274
Schizophrenia R-HSA-71288 PMID:22465051
Major depressive disorder R-HSA-8934903 PMID:27063986
Type 2 diabetes mellitus R-HSA-8939245 PMID:19667185
Schizophrenia R-HSA-5683371
Sjogren’s syndrome R-HSA-389661
Table 4: Top 10 disease–pathway predictions derived from NN2.
We find literature support for 7 out of the top 10 predicted disease–pathway associations (see Table 4). Further-
more, we find indications that the first association and penultimate associations could be true as well. The lactose
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Figure 3: Precision-recall (left) and ROC (right) curves of our disease–pathways associations predictions.
synthesis pathway (R-HSA-5653890) contains three genes: LALBA, SLC2A1, and B4GALT1. All of those genes
might be associated with autistic disorders. One patented method to detect autistic disorder (US20140349977A1)
includes LALBA as one of the genes of interest. SLC2A1 mutation has been reported in patients diagnosed with
autism [42]. And finally, B4GALT1 has been linked with developmental disorders [43]. The pathway R-HSA-5683371
is linked to the eye disease Microphthalmia. It is known that schizophrenia is linked to eye abnormalities [44]. Among
the 28 genes involved in that pathway, 12 have been linked to the disease in the literature (GOT2, PDHA1, DLD,
GCSH, DLAT, PDHB, DAO, OGDH, DHTKD1, GNMT, DDO, PRODH2).
These results show the relevance of our framework for de novo disease–pathway associations prediction despite
relatively low retrieval scores against the ground–truth.
Predicting disease–gene associations
For each model, we compute disease–gene association scores as described in Methods and we test the validity of our
predictions against DisGeNET database [40]. We compare the entire set of predictions against two baselines: the
Frequency of Differential Expression (FDE) and the approach introduced by Zhao et al. [8] for de novo disease–gene
association prediction (Katz).
In FDE, the score of a disease–gene association corresponds to how frequently that gene is consistently differ-
entially expressed in patients having the disease, i.e., for disease d and gene g, the association score, sdg, is given
by
sdg =
∣∣∣∣∣∣
1
|Pd|
∑
p∈Pd
Xgp
∣∣∣∣∣∣ , (4)
where we amalgamate entities (disease, gene, and patient) with their indices, Pd denotes the set of patients having
disease d, and X corresponds to the data matrix introduced in Methods.
The Katz method uses disease specific Protein–Protein Interaction (PPI) network, where each node of a standard
PPI network is associated to a score (here based on the FDE of each gene for the disease considered). The authors
then use Katz-centrality on each disease PPI network to define a final score for each disease–gene association. The
higher the score, the higher the association is expected to be true. We download the PPI data from BioGRID [45]
and IID [46] and create our PPI network from the union of both databases restricted to our set of genes. Finally,
we perform a grid-search to identify the best parameters for the model by trying to maximise the area under the
precision-recall curve metric.
We evaluate the results as done previously for disease–pathway associations (see Figure 4). Interestingly, we
observe that the FDE score is a poor predictor of disease–gene associations (worse than random). We further
observe that NN2 and NN3 are the best performing models for this task with Katz coming third. However, overall
the performances for disease–gene association predictions are limited and the improvement over existing methods
is marginal. The relatively poor performances can be partially attributed to the incompleteness of the reported
disease–gene associations in DisGeNET. As an additional analysis, we search the literature for support for the top
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10 predicted disease–gene associations by the best performing model, NN2 (see Table 4). To mitigate circularity in
the argument, we make sure than none of the supporting literature we found is based on any of the datasets we used.
Note that none of those associations are reported in DisGeNET.
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Figure 4: Precision-recall (left) and ROC (right) curves of our predictions for disease–genes associations.
Disease Gene Literature support
Asthma UBB
Prostate cancer RPS27A PMID:15647830
Autistic disorder FGF20 PMID:19204725
Alzheimer’s disease FGF23 PMID:26674092
Schizophrenia RHOA PMID:16402129
Amyotrophic lateral sclerosis PSMD13
Amyotrophic lateral sclerosis CASP3 PMID:11715057
Chronic obstructive pulmonary disease SKP1 PMID:23713962
Autistic disorder PSMB2
Irritable bowel syndrome PSMA1 PMID:28717845
Table 5: Top 10 disease–gene predicted by NN2.
We are able to find literature support for 70% of the top 10 predicted disease–gene associations (see Table 5).
Furthermore, there are some indications that could link amyotrophic lateral sclerosis (ALS) to PSMD13. On the
one hand, ALS onsets occur typically after age 50 and manifest partially through muscle weakness. Also, PSMD13
is linked to aging [47] and high expression of the gene has been found in skeletal muscle of athletes [48], suggesting
that under-expression could be a sign of muscle weakness. These results validate the relevance of our framework for
de novo disease–gene association prediction.
3 Conclusions
In this study, we propose a multi-scale neural-network based framework that integrates gene expression data associ-
ated to diseases with gene–pathway, gene–complex, and complex–pathway information. Our integrative framework
allows for simultaneously uncovering of novel disease-disease associations and disease molecular mechanisms from
patient gene expression profiles through the analysis of trained neural networks. We show that the NNs achieve good
diagnosis prediction accuracies on our dataset showing the validity of our integrative process. Furthermore, we show
that the associations predicted from the trained models are biologically meaningful and supported by the literature,
thus validating our approach.
While our disease molecular mechanisms are strongly supported by the current knowledge about these diseases,
a next step would be to identify among the predicted genes and pathways suitable biomarkers and drug targets that
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could be used to improve diagnosis, prognosis, and treatment. We leave this for future work. Also, while our multi-
scale NN framework integrates the hierarchical functional organization of a cell (from genes to protein complexes
and biological pathways), our methodology can be extended to include any dataset pertaining to diseases of interest,
e.g., uncovering molecular mechanisms of cancer from patient somatic mutation profiles.
Finally, while we focus on patient data with application to diseases, our methodology can be extended to integrate
additional omics data with the objective of getting more biologically accurate models for the analyses of patients,
tissues, and cells. Some further applications include studies of diseases linked to a specific tissue, studies of cell’s
specialization, and any study that can benefit from the integration of the hierarchical functional organization of cells.
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